Skip to main content

Table 1 Characteristics of 111 RA patients

From: Correlation of antinuclear antibody and anti-double-stranded DNA antibody with clinical response to infliximab in patients with rheumatoid arthritis: a retrospective clinical study

Baseline (before starting IFX)  
   Female, age (mean ± SD, range) 91/111 (82%), 51.6 ± 13.3 years (21 ~ 80)
   Disease duration (mean ± SD, range) 6.6 ± 6.4 years (4 months ~ 32 years)
   DAS28 (ESR) (mean ± SD, range) 5.37 ± 1.33 (1.71 ~ 8.41)
   MTX (mean ± SD, range) (used in all the patients), 8.1 ± 1.6 mg/week (4 ~ 14 mg)
   Corticosteroids users 68/111 patients (61%)
   PSL dosage (mean ± SD, range) 6.2 ± 3.2 mg/day (2 ~ 16 mg)
At the study point  
   Total number of IFX (mean ± SD, range) 13.0 ± 7.3 times (3 ~ 38)
   DAS28(ESR) (mean ± SD, range) 3.55 ± 1.64 (0.54 ~ 7.84)
   EULAR response Good response 55% (including remission 38%)
  Moderate response 18%
  NOR 27% (including LOR 21%)
   Discontinuation 45/111 (41%)
   Reasons for discontinuation Remission, eight; NOR, 21; adverse events, 14;
  financial reasons, two
  1. IFX, infliximab; LOR, loss of response; MTX, methotrexate; NOR, no response; PSL, prednisolone.